MedTrace Logo

Normotensive and Hypertensive Placental Abruptions

NCT04449601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2020-06-29

No results posted yet for this study

Summary

Placental abruption is a significant cause of both maternal morbidity and neonatal morbidity and mortality. Most abruptions accept to be related to a chronic placental disease process. Therefore, it is very important to understand these processes. To analyze maternal and neonatal effects of placental abruption(PA) through a novel classification in the presence of hypertension. Initial hemoglobin parameters were also compared to predict pregnancy outcomes in addition to hypertension.

Conditions

  • Abruptio Placentae; Affecting Fetus or Newborn

Interventions

OTHER

clinical assesment

Comparison of Hypertensive group and normotensive group

Sponsors & Collaborators

  • Hatice Akkaya

    lead OTHER_GOV

Principal Investigators

  • Hatice Akkaya, Ass Prof · Kayseri Education and Research Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2017-04-30
Completion
2017-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04449601 on ClinicalTrials.gov